Silver is chief financial officer and head of corporate development at Freeline Therapeutics Holdings plc, a clinical-stage systemic gene therapy company.
Prior to joining Freeline in 2018, Silver was partner and head of biotechnology in the healthcare practice at Perella Weinberg Partners, an independent global advisory firm.
Prior to Perella Weinberg, Silver held a number of positions in Morgan Stanley's healthcare investment banking group, most recently as Managing director from 1998 to 2013.
He began his career in the corporate transactions group at Sullivan and Cromwell. His advisory experience spans dozens of transactions, including mergers and acquisitions, joint ventures and licenses, and capital raises across the equity, debt, convertible and royalty finance markets.
TScan discovers and develops T cell therapies (TCR-T) to treat liquid cancers, solid tumors, and other serious diseases.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business